| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidate Candidate's Name , Ph.D. HCLD/CC (ABB)
E-mail Address: EMAIL AVAILABLE
Office Phone: PHONE NUMBER AVAILABLE
Cell Phone: PHONE NUMBER AVAILABLE
Street Address -22-2024
APPOINTMENTS/EMPLOYMENT
Faculty Appointment:
06/2024- Present Associate Professor
Department of Pathology, Molecular and Cell-Based Medicine
Icahn School of Medicine at Mount Sinai,
New York, NY 10029
03/2018 05/2024 Assistant Professor,
Department of Pathology, Molecular and Cell-Based Medicine
Icahn School of Medicine at Mount Sinai,
New York, NY 10029
Clinical Appointment
03/2018 Present Assistant Director
Molecular Pathology Lab, Center of Clinical Labs,
Mount Sinai Healthcare System, New York
EDUCATION
1997-2000 B.S., Chemistry and Zoology
University of Kanpur, India
Department of Biology
2000-2002 M.S., Biotechnology
Purvanchal University, India
Department of Biotechnology and Biochemistry
2003-2010 Ph.D.
Molecular Biology and Genetic Engineering Department, CSIR-NBRI
and University of Lucknow, India
Mentor: Dr. Devendra V Amla
11/2011-02/2018 Postdoctoral Fellow
Clinical Genetics and Molecular Diagnostics Lab
Division of Pathology and Laboratory Medicine,
The University of Texas MD Anderson Cancer Center, Houston, Texas
1
Mentor: Dr. Rajyalakshmi (Raja) Luthra; Co-mentor: Dr. Keyur Patel
CERTIFICATION
2020 - Present NYS Department of Health Certificate of Qualification (COQ)
Category: Oncology- Molecular and Cellular Tumor Markers
2022 - Present American Board of Bioanalysis (ABB) Technical Supervisor (TS)
(Certification ID: 20202617)
2023 - Present American Board of Bioanalysis (ABB) High Complexity Laboratory Director
(HCLD) (Certification ID: 20202617)
2024- Present American Board of Bioanalysis (ABB) Clinical Consultant (CC) (Certification
ID: 20202617)
Pending Certifications:
2024 - American Board of Clinical Chemistry (ABCC) Molecular Diagnostics
(Active candidate)
2024 - NYS Department of Health Certificate of Qualification (COQ)
Category: Engraftment monitoring (Pending submission)
2024 - NYS Department of Health Certificate of Qualification (COQ)
Category: Genetics (Pending submission)
HONORS/AWARDS
2005 CSIR-Diamond Jubilee Research Fellowship Award, India.
2007 CSIR-Senior Research Fellowship Award, India.
2007 Best Poster Award, 76th Annual General Meeting of Society of Biological Chemist, India
2016 Best Presentation Award at Cancer Genomic Consortium (CGC) - Meeting 2016, Denver, USA
PROFESSIONAL ROLES
2017 - Present Ad Hoc Reviewer: Cancer Cytopathology, Cancer Genetics, Oncotarget, Scientific
Reports; Cancers
2018 - Present Active Member, Multidisciplinary Myeloma Tumor Board, Mount Sinai Hospital
2019 - Present Faculty Interviewer for Mount Sinai Molecular Pathology Fellowship Program
2019 - Present Faculty Interviewer for Mount Sinai Pathology Residency Program
2019 - Present Faculty Member of Resident Evaluation Committee, Department of Pathology,
Molecular and Cell-Based Medicine, Mount Sinai Hospital
2
2023 Present Committee Member of Center for Asian Equity and Professional Development s
(CAEPD) Education and Research Committee, Mount Sinai Hospital
2022 Co-chair and Moderator at Annual Meeting Cancer Genomics Consortium (CGC) 2022
for the session on What is New in Genomics of Solid Tumors?
2023 Member of Scientific Program Committee, Cancer Genomic Consortium (CGC)
Annual Meeting 2023
2023 Member of Sub-Committee on Round Table Sessions, Cancer Genomic Consortium
(CGC) Annual Meeting 2023
2023 Moderator of Speed Abstract Session of Analytic and post analytic improvements in
Genomics for the establishment of efficient clinical workflows and management in
patient care Annual meeting CGC 2023
2023 Registered External CAP Inspector for the College of American Pathologists
2023 Member of The Compendium of Cancer Genome Aberrations (CCGA) knowledgebase
workgroup
2023 Editorial Board Member, Frontiers in Cell and Developmental Biology
2023 Review Editor Member, Molecular and Cellular Pathology
Professional Memberships:
2015- present Active Member, Association of Molecular Pathology (AMP)
2015- present Active Member, Cancer Genomics Consortium (CGC)
2021- present Active member, American Association of Bioanalysts (AAB)
CLINICAL PROFILE
My clinical postdoctoral fellowship at the Molecular Diagnostic Laboratory of MD Anderson helped me
to gain comprehensive insights into the operations of a high-complexity clinical laboratory. The tests I
validated and implemented are high impact tests, routinely offered as clinical service for patient care.
After joining as an Assistant Director of the Molecular Pathology Lab, MSHS, in 2018, I secured a
Certificate of Qualification (COQ) for oncology-molecular and cellular tumor markers and board
certification in High Complexity Laboratory Director (ABB). I oversee and routinely sign out molecular
oncology diagnostic tests, ensuring the provision of accurate and timely results. My duties include
establishing clear objectives, method validation, staff training, competency evaluation, and QI projects.
Some of these QI projects helped to reduce duplicate/incorrect ordering and became key performance
indicators as a part of the Quality Assurance program for the lab. I constantly strive to broaden the
spectrum of clinical offerings, making high-quality testing accessible and affordable for the patients care.
Clinical Practice Size
I annually sign out 3000-4000 oncology cases as a primary molecular director. These are high-complexity
tests and require specialized expertise to interpret the results. Each test involves Quality Control and
technical review, followed by result interpretation and report generation according to clinical indication
3
for each case before sign-out. These cases involve high-volume tests routinely performed in the
laboratory.
Tumor Boards
I present molecular pathology test results in weekly tumor boards or sign-out conferences. My molecular
findings helped clinicians to understand the case on a molecular level and correlate with pathologic and
radiologic findings. This allowed them to understand disease pathogenesis and make clinical decisions for
disease management.
Clinical Consultations
I regularly communicate with the referring physicians regarding the clinical significance of the laboratory
findings and ensure that the results reports include pertinent information required for specific patient
interpretation and management. Besides this, I had done Ad hoc consultations related to clinical and
technology application to different clients for third party.
Test Validation
I implemented novel billable assays using advanced technologies to increase the test menu for clinical
service. These assays directly affect the diagnosis and treatment of the patients. These contributions
results in a steady increase in test menu, increased test volume, and increase in the laboratory's
infrastructure. Some of the test clinically implemented and offered as clinical service for patient care:
2015: Detection, genotyping, and monitoring of CALR mutations in myeloproliferative neoplasms.
(CLIA approved; 1300 cases)
2016: Genotyping of cell-free nucleic acids for biomarker detection using ddPCR and NGS (CLIA
approved; 6000 cases).
2017: Detection of EGFR T790M mutation in cytological specimens by ddPCR in lung carcinoma. CLIA
approved)
2017: NGS-based comprehensive profiling of TP53 gene for tumor burden monitoring and clonal
evolution in CLL patients. (CLIA approved; 1000 cases tested)
2019: Implementation of SARS-CoV-2 testing
2021: Qualitative BRAF V600 mutation analysis by Real-Time PCR using the IdyllaTM system
(NYSDOH approved; Project ID: 85439). (120 cases tested).
2022: Clonality assessment of T cell receptors (TCR Gamma and TCR Beta) by Next-generation
Sequencing (NYSDOH approved; Project ID: 92760). (600 cases tested)
2022: Implementation of Molecular LIMS system SoftMolecular.
Validated tests Pending NYSDOH submission\approval
Solid tumor profiling using 500 genes Oncomine Comprehensive Assay plus panel to detect SNVs,
insertion, deletion, copy number, RNA fusions and tumor mutation burden. (Submitted for approval)
Rapid EGFR and KRAS mutation testing for lung and colorectal cancer patients by Real-Time PCR
using the IdyllaTM System.
Improvise Workflows
I continue to provide consistent, reliable results for existing tests through standardization and
harmonization by using new instruments or nearly identical materials to provide clinically similar results.
Some of the validations I spearheaded to simplify the workflow, reduce the number of repeats (due to
technical and manual errors), and turnaround time of approved testing include:
Validation of Pyromark 48 instrument for MGMT methylation analysis for gliomas. (Full automation
reduced labor time and manual errors)
4
Transfer of JAK2 and MYD88 quantitative test on Quantstudio platforms from Roche light cycler.
(Automated data analysis, with improved workflow)
Transfer of manual nucleic acid extraction process to semi-automated extraction on Qiacube Connect.
(Reduce labor time, less manual errors and faster turnaround time)
Transfer of BCR::ABL testing from clear to white plates. (Cost effective)
Validation of new PCR thermocyclers. (Improve technical efficiency by reducing number of repeats)
Verifying the workflows and accurate clinical reporting during the Integration of the SoftMOL LIMS
system in the molecular laboratory. (Reduce labor time due to paper free testing, simplified reporting
and data analysis; Improve efficiency and enhance data accessibility)
In summary, leveraging my more than nine years of clinical experience, I possess the confidence and
expertise required to make informed clinical decisions and craft and refine molecular pathology test
reports.
CLINICAL LEADERSHIP/SENIOR ADMINISTRATION
The consolidated section of the Molecular Pathology Lab at Mount Sinai has over 10 medical
technologists, 1 laboratory supervisor, and 1 laboratory operation manager, and performs approximately
11,000 clinical tests per year. As an Assistant Director of the section, my primary role is to- 1) Provide
and maintain a high standard state-of-the-art molecular diagnostic for patient care; 2) Ensure accurate
reporting of the test results by maintaining quality control and improvement programs; 3) Develop and
implement novel molecular-based strategies that improve diagnosis and treatment modalities.
Some of Key responsibilities in this role include:
Clinical reporting and consultation
Review genomic data according to AMP/CAP guidelines; regularly update variant curation strategies,
interpretation and reporting processes
Verify and validate information on test reports to guarantee accuracy and completeness.
Provide timely consultation and interpretation of test results to healthcare providers through electronic
communication or telephone conversations.
Address general inquiries regarding reported results or test related questions from pathologists,
oncologists, and physicians/providers.
Uphold the highest standards of quality in test reporting and result interpretation by reviewing the
quality control, medical interpretation for test results and making sure the results reported is in
compliance with established SOP.
Direct the Technical and Scientific Operation
Annually review of SOPs for test systems, establishing verification and documentation procedures for
testing methods. Ensure test performed complies with regulatory standards (CLIA, NYSDOH, CAP).
Develop technical and analytical standards for any minor or significant change in the established
method or new instrument evaluation.
Direct laboratory staff to Investigate and troubleshoot laboratory incidents. Review non-conformance
and incident reports for compliance with the Quality Management System (QMS).
Engage with clinician to increase the test menu for larger patient population testing. Based on
discussion implement efficient workflows or customize assays in order to meet the discussed objectives.
Review proficiency test results and report to CAP website in timely manner.
Designed and implemented quality metrics for the NGS pipeline and verify any changes associated with
software upgrades.
Serves as a mentor in technical and administrative procedures for the supervisor(s).
5
Quality management and assurance
Develop and maintain total quality management aligned with the laboratory mission.
Establish and monitor a comprehensive quality control program to maintain acceptable levels of
analytical performance for each test system.
Assure the delivery of quality results across various clinical tests and aggregate laboratory data for
continuous improvement.
Ensure the quality management system's conformance with NYSDOH Clinical Laboratory Practice
Standards and other regulatory bodies.
Streamline the process for preparing laboratory for regulatory inspections by reviewing molecular CAP
checklist and make sure laboratory is prepared for on-site inspections by conducting mock inspections.
Review quarterly quality reports for each established element and discussed monthly with the quarterly
department QA meetings with the System QA director.
Administer a comprehensive quality assurance program at all practice levels.
Directed quality improvement projects in laboratory to improve the efficiency of molecular testing and
turnaround time in the clinical laboratory.
Strategic and operational planning/program development
Directs plans, organizes, and evaluates the administrative near and long-term operational goals and
objectives in compliance with regulatory standards along with the laboratory director.
Promote a safe laboratory environment for personnel.
Assists with cost analyses and budget development. Provides recommendations regarding capital
equipment acquisition.
Responsible for determining space and resource requirements. Communicate these needs to the System
administrator.
Administrative management
Participate in the recruitment and interview processes for new employees, fellows, or residents and
offer practical recommendations for hiring decisions.
Provide competency evaluation and oversee protocol compliance for all laboratory personnel.
Manage annual proficiency benchmarking and ensure appropriate staff enrollment in proficiency
testing programs.
Perform annual Performance appraisals and sign off on personnel training competency reviews.
Organize and provide direction in lab meetings and continuing education seminars for team members
to earn annual CE credits.
RESEARCH PROFILE
During my doctoral studies, I cultivated a robust molecular biology background. My postdoctoral
fellowship at MD Anderson Cancer Center honed my focus on clinical research. This dual expertise
empowered me to spearhead impactful research and clinical initiatives to enhance patient care. My
research focused on developing molecular strategies in the areas of genomics, epigenomics, and
transcriptomics for cancer diagnostics, theragnostics, and prognostics. My tenure of 6 years resulted in 29
manuscripts, 2 book chapters, and 17 abstracts in peer-reviewed journals, including the Journal of
Molecular Diagnostics (IF 5.3), Modern Pathology (IF 8.2), and Annals of Oncology (IF 51.76). Key
accomplishments include:
Streamlining complex molecular assays for genotyping hematological, solid tumors, and liquid
biopsies for patient care.
Pioneering molecular testing using challenging specimens and their utility for increasing diagnostic
yield of lung and thyroid cancers.
6
Initiating quality improvement projects to enhance molecular testing efficiency and improving
turnaround time.
After joining Mount Sinai, my clinical research projects expanded the clinical test menu, improved
workflows, and tested challenging specimens. I revolutionize cancer diagnosis by utilizing discarded FNA
washes as a molecular diagnostic sample, eliminating the need for additional biopsies. I collaborated with
clinicians and pathologist for providing molecular component of the study. These studies resulted in 9
manuscripts and 17 abstracts, including Neuro-Oncology (IF 15.9), Blood Advances (IF 7.5), Diagnostic
Cytopathology (IF 2.8), Cancer Investigation (IF 2.2), Medicine Care (IF 3.0) and external grant funding
applications. Overall, my publications received a total of 1370 citations.
OVERALL IMPACT
Leveraging advanced technology and innovative approaches, I have played a pivotal role in enhancing
clinical services by increasing the offered test menu, clinical consultation, and management for improving
patient care. By continuously seeking opportunities to improve the clinical workflows, I spearheaded the
establishment of extraction workflows from diverse and challenging specimens (FFPE, Diff quick, Blood
and FNA smears, specimens with limited tissue and peripheral blood) for in house clinical testing, send-
out the extracted nucleic acid from these specimens to our external collaborators, and expediting crucial
information to clinicians. These improvements improved efficiency and reduced the chances of manual
errors through automation of extraction procedures.
I established rapid testing for BRAF V600 mutations testing, delivering results within 24 Hrs. This rapid
diagnosis assists clinicians in timely starting the targeted treatment, which significantly contributes to
improved patient care and outcomes, underscoring the impact of my work. Amidst the challenges posed
during pandemic, I played a crucial role in establishing a real-time PCR-based SARS-CoV-2 assay, which
has been instrumental in measuring viral load of positive patients, facilitating timely patient management
during this global health crisis. Furthermore, I am currently engaged in the clinical implementation of
several molecular diagnostic assays in the clinical laboratory, such as the Oncomine comprehensive 500
assay, Rapid EGFR and KRAS assay for solid tumor profiling, and MRD testing for NPM1 gene using
droplet digital PCR in AML. Successful validation and integration of these assays into our laboratory s
repertoire will advanced in-house testing, reducing turnaround times and ultimately benefiting patient
care. In addition to my clinical duties, I am actively involved in various research projects to develop
biomarker assays for early cancer detection and disease monitoring. One notable project addresses the
challenge of limited sample volume by investigating the use of centrifuged FNA washings, typically
discarded by cytology labs, for molecular profiling. This innovative approach enables the establishment
of differential diagnoses for patients with advanced lung malignancies and identifies molecular
biomarkers to guide treatment decisions. I have published multiple peer-reviewed articles in high-impact
journals, and presented 32 poster/platform presentations at national and international conferences. These
contributions have enhanced our understanding and allowed us to share our discoveries with the wider
scientific and medical communities. Within the laboratory, I conducted quality improvement projects, to
address and improve issues of duplicate ordering, lack of requisition, and incorrect test ordering. These
improvements have enhanced our quality assurance program, ensuring that our lab operates at the highest
standards of accuracy and efficiency. Education has always been a core value for me, and I am committed
to developing future pathologists and professionals by teaching residents about advanced molecular
technologies and data interpretation from complex molecular diagnostic tests. I am an active member of
multiple national and international societies, including the AMP, CGC, and AAB. These memberships
reflect my commitment to staying connected with peers, sharing knowledge, and contributing to
advancing molecular pathology on a global scale. In conclusion, my tenure at Mount Sinai has been
marked by a relentless pursuit of excellence in molecular diagnostics.
MENTORING PROFILE
7
I mentored, supervised, and trained undergraduate (6) graduate (1) residents (1-2 residents/month),
molecular pathology fellows (5), and LGG fellows (3) who rotated through the MDACC and Mount Sinai
Molecular Pathology Laboratories. I trained them to understand the need for high-complexity testing, data
analysis, result interpretation and improve the concerning areas to meet their goals. I assisted residents
and fellows in data acquisition and interpretation of molecular results for their research projects. Some of
these efforts helped them achieve an outstanding scientific presentation award. I mentored and assisted
Dr. Tremblay (LGG Fellow) in data compilation for her abstract submission. She is the recipient of
Young Investigator Award and Platform presentation for this work at AMP 2023. I am proud that all our
molecular pathology fellows have moved to occupy major academic positions. In a laboratory setting, I
mentored laboratory personnel, including laboratory technicians, supervisors, and managers, to guarantee
employees' professional development and enhance my experience in staff development and supervision.
This allow me to lead, and mentor high-performing teams committed to achieving collective goals. One
of the laboratory technologist (Mr. Lam) and supervisor (Mrs Reddy) I directly mentored promoted to
Laboratory Operation Manager at MSHS and Senior Manager at Moderna. I will continue to enhance my
mentoring skills by participating in local, regional, and national development activities to improve my
overall personal development and increased my productivity as an individual.
DIVERSITY AND INCLUSION IMPACT
I am fortunate to serve in Institutions as MD Anderson Cancer center and Mount Sinai Health Care and
oversee patient clinical testing for disease diagnosis and monitoring of the most diverse patient
population, which contains a significant portion of ethnic minorities. As a clinical faculty in the
Department of Pathology and Assistant Laboratory director, I have mentored and trained laboratory
technicians, supervisors, managers, undergraduate and graduate students, pathology residents, and fellows
from various backgrounds and countries. I serve as an interviewer for recruiting laboratory staff,
pathology residents, and fellows and have been part of efforts to recruit or retain residents and staff from
diverse backgrounds and those underrepresented in medicine. Currently, I serve in the Mount Sinai Center
for Asian Equity and Professional Development s (CAEPD) Education and Research Committee and co-
leading a project associated with data analysis of the promotion and titles of AAPI personnel at MSHS. I
serve as a member of different professional societies such as AMP, CGC, ABB, and CCGA workgroups.
I served on the program committee for the annual CGC 2023 meeting, which helped me to increase my
professional network with peers and colleagues with diverse backgrounds and work together for the
organization s goal to increase inclusion, diversity, and equity. My publications included authors from all
backgrounds as well so that that diversity of authorship could mirror the diversity of colleagues and
learners. As I move forward in my career, I will continue to promote aspects of equity and inclusion in
my clinical work.
GRANTS, CONTRACTS, FOUNDATION SUPPORT
List Funding Source Role in Project Status
Title: Enhanced Molecular Co-Investigator Reviewed and Scored (26)
Diagnostics in NSCLC: Not Funded
Analytical and Clinical
Validation of Cytology Washes
UH2 CA272892-01
TRAINEES
8
Name Level of Trainee Role in Training & Trainees Current
Inclusive Dates of Training Training Venue Status/Employment
David Suster Molecular Trained for High throughput Mount Sinai Assistant professor,
Genetic Fellow molecular testing (NGS), test Hospital, NY Department of Pathology and
(2019-2020) validation and analytical Laboratory Medicine, Rutgers, The
concepts, routine clinical State University of New Jersey
testing and data interpretation,
help to prepare for tumor
board presentation.
Martina Risech Molecular Trained for High throughput Mount Sinai Assistant Professor,
Genetic Fellow molecular testing (NGS) and Hospital, NY St Luke Hospital, Philadelphia, PA
(2020-2021) result interpretation, QC
review.
Beerinder Karir Molecular Trained for High throughput Mount Sinai Johnson and Johnson clinical labs
Pal Genetic Fellow molecular testing (NGS) and Hospital, NY
(2021-2022) result interpretation and
routine clinical testing result
interpretation, help to prepare
for tumor board presentation.
Omid Rashidpur Molecular Trained for High throughput Mount Sinai Assistant Professor,
Genetic Fellow molecular testing (NGS) and Hospital, NY University of Alberta, Canada
(2022-2023) result interpretation and
routine clinical testing result
interpretation, QC review,
help to prepare for tumor
board presentation.
Residents Pathology Trained for different routine Mount Sinai Pathology Residency Program
(Every month 1- Residency clinical molecular test, NGS Hospital, NY
2) (PGY1-PGY4) techniques and data
(2018- Present) interpretation,
LGG fellows Laboratory Trained for different Mount Sinai ABMGG Fellowship Program
(Every year 2-4) Genetics & molecular pathology test, Hospital, NY
Genomics Fellow NGS techniques and data
interpretation, review of
different databases, clinical
test validation concepts, help
to prepare for tumor board
presentation, QC review.
Ana Bolivar Undergraduate Trained for high throughput MD Anderson Graduate Research T32 Fellow at The
Student technologies (Liquid biopsy Cancer center, University of Texas MD Anderson
(2016-2017) NGS and Digital PCR) Houston Cancer Center, Houston
Shara Kamil Graduate student: Liquid biopsy for profiling MD Anderson Faculty in UOS- College of Medicine-
Zheer Iraqi Women lung tumors by using ddPCR Cancer center, Department of Medical Education, Iraq
Nizamuddin Fellowship Houston
Foundation
(IWFF) Fellow at
UT_MDACC
USA
Brett Hanningan Undergraduate Liquid biopsy for profiling MD Anderson Field Application Scientist in
Student lung tumors by using NGS Cancer center, Thermofisher Scientific, Houston
(2016-2018) Houston
Khushali Patel Undergraduate Trained for high throughput MD Anderson Senior Medical technologist, MD
Student technologies (NGS and Cancer center, Anderson Cancer Center, Houston
(2014-2016) Digital PCR) and mentored Houston
9
for internship
TEACHING ACTIVITIES
As an Assistant Professor in the Department of Pathology, Molecular and Cell-based Medicine of Icahn
School of Medicine at Mount Sinai, I mentored and delivered lectures in classroom setting to medical
residents and fellows for molecular pathology curriculum.
Courses taught
Teaching Activity/Topic Level Role Level and Number of Number of Years
Learners Taught, and hours Taught
Venue week/month/yr
Technical Considerations for Pathology Residency Lecturer Residents, 12-20, 1 / Year 2018,
Molecular Diagnostics in Solid program Mount Sinai Hospital 2021
tumors
Molecular Diagnostics of Lung Pathology Residency Lecturer Residents, 12-20, 1 / Year 2021
and Skin Diseases program Mount Sinai Hospital
Technical Considerations for Pathology Residency Lecturer Residents, 12-20, 1 / Year 2020,
Molecular Diagnostics in program Mount Sinai Hospital 2022
Hematological Diseases
Molecular Diagnostics of the Pathology Residency Lecturer Residents, 12-20, 1 / Year 2020,
Myeloid Lineage Diseases program Mount Sinai Hospital 2022
Practices in Current Clinical Heme Oncology Lecturer Fellows, 10-12, 1 / Year 2020
Molecular Screening Fellow Mount Sinai Hospital
PUBLICATIONS
(H index: 20; Total citations: 1370; i-10 index: 27; Cumulative IF: 314.93)
Peer-Reviewed Original Contributions
1. Mehrotra M, Singh A, Sanyal I, Altosaar I, Amla D (2011) Pyramiding of modified cry1Ab and
cry1Ac genes of Bacillus thuringiensis in transgenic chickpea for improved resistance to pod borer
insect Helicoverpa armigera. Euphytica 182: 87-102. (IF: 2.185)
2. Mehrotra M, Luthra R, Ravandi F, Sargent R, Barkoh B, Abraham R, Mishra B, Medeiros J, Patel K
(2014) Identification of Clinically important chromosomal aberrations in acute myeloid leukemia by
array-based comparative genomic hybridization. Leukemia and Lymphoma 55(11): 2538-48. (IF:
2.996)
3. Wang S, Hasserjian R, Fox P, Rogers S, Geyer J, Richards D, Weinzierl E, Hatem J, Jaso J,
Shamanna R, Stingo F, Patel K, Mehrotra M, Bueso-Ramos C, Young K, Dinardo C, Verstovsek S,
Tiu R, Bagg A, His E, Arber D, Foucar K, Luthra R, Orazi A (2014) Atypical chronic myeloid
leukemia (aCML) BCR-ABL1-Negative is clinicopathologically distinct from unclassifiable
myelodysplastic/ myeloproliferative neoplasms. Blood 123: 2645-2651. (IF: 25.669) Data acquisition
and data analysis.
10
4. Loghavi S, Curry J, Cabala C, Ivan D, Patel K, Mehrotra M, Bassett R, Prieto V, Tetzlaff M (2014)
Melanoma arising in association with blue nevus: A clinical and pathologic study of twenty-four
cases and comprehensive review of the literature. Modern Pathology 27(11); 1468-78. (IF: 8.209).
Data acquisition and data analysis.
5. Mehrotra M, Medeiros L, Luthra R, Sargent R, Yao H, Barkoh B, Singh R, Patel K (2014)
Identification of putative pathogenic microRNA and its downstream targets in ALK negative
anaplastic large cell lymphoma. Human pathology 45; 1995-2005. (IF: 3.526)
6. Falchi L, Mehrotra M, Newberry K, Lyle L, Lu G, Patel K, Luthra R, Popat U, Verstovsek S (2014)
ETV6-FLT3 fusion gene positive, eosinophilia-associated myeloproliferative neoplasm successfully
treated with sorafenib and allogeneic stem cell transplant. Leukemia 28; 2090-2092. (IF: 12.897)
Data acquisition and data analysis.
7. Mehrotra M, Luthra R, Barkoha B, Galbincea J, Mehta P, Singh R, Goswami R, Jabbar K, Patel K
(2015) Clinical validation of a multi-purpose assay for detection, genotyping and monitoring of CALR
mutations in myeloproliferative neoplasms. American Journal of Clinical Pathology 144(5):746-55.
(IF: 5.4)
8. Mehrotra M, Patel K, Miranda R, Chen T, Muddasani R, Zuo Z, Mishra B, Abraham R, Luthra R,
Lu G (2015) Genomic and clinicopathologic features of primary myelofibrosis with isolated 13q
deletion. Cancer Lymphoma, Myeloma and Leukemia 15(8):496-505. (IF: 2.822)
9. Yin C*, Jain N*, Mehrotra M*, Zhang J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch
G, Wang S, Medeiros J, Chin L, Kantarjian H, Patel K, Ravandi F, Futreal A, Bueso-Ramos C (2015)
Identification of a cryptic fusion oncogene IRF2BP2-RARA in variant acute promyelocytic leukemia.
Journal of the National Comprehensive Cancer Network 13 (1); 19-22. (*Co-first author) (IF: 13.4)
Data acquisition and data analysis.
10. Loghavi S, Pemmaraju N, Kanagal R, Mehrotra M, Medeiros L, Luthra R, Lin P, Huh Y, Kantarjian
H, Cortes J, Verstovsek S, Patel K (2015) insights from response to tyrosine kinase inhibitor therapy
in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125 (21):3360-3.
(IF: 25.669). Data acquisition and data analysis.
11. Singh R, Murugan P, Patel L, Voicu H, Yoo Y, Majewski T, Mehrotra M, Khalida W, Tannir N,
Karam J, Jonasch E, Creighton J , Medeiros J, Broaddus R, Tamboli P, Baggerly K, Aldape K,
Czerniak B, Luthra R, Sircar K (2015) Intratumoral morphologic and molecular heterogeneity of
rhabdoid renal cell carcinoma: Challenges for personalized therapy. Modern pathology 28(9):1225-
35. (IF: 8.209). Data acquisition and data analysis.
12. Patel K, Newberry K, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort M,
Luthra M, Manshouri T, Santos FPS, Kantarjian H, and Verstovsek S (2015) Correlation of mutation
profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126 (6):790-7. (IF:
25.669). Data acquisition and data analysis.
13. Singh R, Mehrotra M, Chen H, Salim A, Sahin A, Patel K, Routbort M, Lu X, Ronald A, Mishra
B, Virani S, Medeiros L, Luthra R (2016) Comprehensive screening of gene copy number
aberrations in formalin-fixed paraffin-embedded solid tumors using molecular inversion probe-based
SNP Array. Journal of Molecular Diagnostics 18(5):676-687 (IF: 4.1). Data acquisition.
14. Loghavi S, Bueso-Ramos C, Shamanna R, Salim A, Routbort M, Mehrotra M, Verstovsek S,
Medeiros L, Luthra R, Patel K (2016) Myeloproliferative neoplasms with calreticulin mutations
exhibit distinctive morphologic features. American Journal of Clinical Pathology 145(3):418-27.
(IF: 5.4). Data acquisition and data analysis.
11
15. Yadav R, Mehrotra M, Singh A, Singh R, Sanyal I, Pande V, Amla D (2016) Improvement in
Agrobacterium-mediated transformation of chickpea by the inhibition of polyphenolics released
during wounding of cotyledonary node explants. Protoplasma 254(1):253-269 (IF: 3.186).
Conception and design of study.
16. Mehrotra M, Duose D, Singh R, Barkoh B, Manekia J, Harmon M, Patel K, Routbort M, Medeiros
L, Wistuba I and Luthra R (2017) Versatile Ion S5XL sequencer for targeted next generation
sequencing of solid tumors in a clinical laboratory. PLOS One 12(8):e0181968. (IF: 3.7)
17. Cote G, Evers C, Hu MI, Grubbs E, Williams M, Hai T, Duose D, Houston M, Bui J, Mehrotra M,
Waguespack S, Busaidy N, Cabanillas M, Habra M , Luthra R, Sherman S. (2017) Prognostic
significance of circulating RET M918T mutated tumor DNA in patients with medullary thyroid
carcinoma. Journal of Clinical Endocrinology and Metabolism 102(9):3591-3599. (IF: 6.134).
Conception and design of study, Drafting and revising critically important content.
18. Mehrotra M, Singh R, Chen W, Richard S, Alaa A, Bedia A, Simien C, Hernandez M, Behrens C,
Patel K, Routbort M, Broaddus R, Medeiros L, Wistuba I, Kopetz S, Luthra R (2017) Study of
preanalytic and analytic variables for clinical next-generation sequencing of circulating cell-free
nucleic acid Journal of Molecular Diagnostics. 19 (4), 514-524 (IF: 4.1)
19. Mehrotra M, Luthra R, Abraham R, Mishra B, Virani S, Chen H, Patel K., Medeiros L and Singh R
(2017) Validation of quantitative PCR-based assays for detection of copy number aberrations in
formalin-fixed, paraffin embedded solid tumor samples. Cancer Genetics 212:213-24-31. (IF: 2.169)
20. Chen H, Singh R, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra B,
Bousamra A, Albarracin C, Wu Y, Chowdhuri S, Shamanna R, Routbort M, Medeiros L, Patel K,
Broaddus R, Sahin A and Luthra R (2017) Genome-wide copy number aberrations and HER2 and
FGFR1 alterations in primary breast cancer by molecular inversion probe microarray Oncotarget
8:PHONE NUMBER AVAILABLE (IF: 0.966). Data acquisition and analysis
21. Mehrotra M, Singh R, Loghavi S, , Duose D, Barkoh B, Behrens C, Patel K, Routbort M, Kopetz S,
Medeiros L, Wistuba I, Luthra R (2017) Detection of somatic mutations in cell-free DNA in plasma
and correlation with overall survival in patients with solid tumors. Oncotarget 24;9(12):PHONE NUMBER AVAILABLE
(IF: 0.966)
22. Ahmadi MP, Singh R, Mahmoodi M, Mehrotra M, Benaim G, Luthra R, Paniz Mondolfi A (2018)
Poorly differentiated osteoclast-like giant cell variant of cutaneous squamous cell carcinoma:
Uncovering its mutational landscape through massive parallel sequencing. Pathol Research and
Practice. 214 (11), 1898-1903. (IF: 2.8). Data acquisition
23. Chowdhuri SR*, Mehrotra M*, Bolivar AM, Shamanna RK, Barkoh B, Hannigan B, Zalles S, Ye
W, Duose D, Broaddus R, Staerkel G, Wistuba I, Medeiros LJ, Luthra R (2018) Salvaging the
supernatant: Next generation cytopathology for solid tumor mutation profiling. Modern Pathology.
31(7):1036-1045. (*Co-first Author) (IF: 8.209)
24. Shah MV, Patel KP, Luthra R, Shamanna RK, Mehrotra M, Bachegowda LS, Champlin RE,
Verstovsek S, and Popat UR. (2018) Sensitive real-time PCR-based monitoring and early detection of
relapse of JAK2 V617F myelofibrosis following allogeneic hematopoietic stem cell transplantation.
British Journal of Hematology 183 (5), 831-835. (IF: 8.615). Data acquisition, analysis, and
interpretation.
25. Jour G, Andeen N, Rohil R, Mehrotra M, Duose D, Hoch B, Argenyi Z, Luthra R, Wistuba I and
Prieto V. (2018) Novel enriched pathways in superficial malignant peripheral nerve sheath tumors
(MPNST) and spindle/desmoplastic melanomas (SDM): Tandem targeted sequencing and gene
12
expression study. Journal of Pathology 244 (1), 97-106. (IF: 9.883). Data acquisition, analysis, and
interpretation
26. Shi X, Duose DY, Mehrotra M, Harmon MA, Hu P, Wistuba II, Kopetz S, Luthra R (2019) Non-
invasive genotyping of metastatic colorectal cancer using circulating cell-free DNA. Cancer Genetics
2321 37:82-89, doi: 10.1016/j.cancergen.2019.06.004 (IF: 2.169). Conception and design of study,
Drafting and revising critically important content.
27. Hannigan B*, Ye W*, Mehrotra M, Vinvet L, Bolivar AM, Zalles S, Barkoh BA, Duose DY, Hu P,
Broaddus RR, Stewart J, Heymach J, Medeiros LJ, Wistuba II, Luthra R, Chowdhuri SR (2019)
Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine needle aspiration
specimens. Annals of Oncology 30,963 969. (IF: 51.769). Conception and design of study, Drafting
and revising critically important content.
Comments: Nature Reviews Clinical Oncology volume 16, page 335 (2019)
This article highlights the clinical utility of FNA supernatant in lung carcinoma and was featured in
Nature Reviews Clinical Oncology as a research highlight Reliable results from several DNA
sources
28. Ye W, Hannigan B, Zalles S, Mehrotra M, Barkoh BA, Williams MD, Cabanillas ME, Edeiken-
Monroe B, Hu P, Medeiros LJ, Stewart J, Luthra R, Chowdhuri SR (2019) Centrifuged supernatants
from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.
Cancer Cytopathology 127 (3), 146-160 (IF: 4.354). Conception and design of study, Drafting and
revising critically important content.
29. Bolivar AM, Luthra R, Mehrotra M, Chen W, Barkoh BA, Hu P, Wei Z, Broaddus RR (2019)
Targeted next-generation Sequencing of tumor and matched circulating tumor DNA in patients with
endometrial cancer. Modern Pathology 32 (3), 405-414. (IF: 8.209). Conception and design of study,
Data interpretation, Drafting, and revising critically important content.
30. Mallampati S, Duose DY, Harmon MA, Mehrotra M, Shamanna RK, Zalles S, Wistuba II, Sun X
and Luthra R (2019) Rational error elimination approach to evaluating molecular barcodes
containing next-generation sequencing data identifies low-frequency mutations in hematologic
malignancies. Journal of Molecular Diagnostics 21(3):471-482. (IF: 4.1). Drafting and revising
critically important content.
31. Bridget M, Farnoud NR, Cassinat B, Lu M, Verger E, McGovern E, Patel M, Martinez JM, Levine
M, Ossa JA, Zhou Y, Kosiorek H, Mehrotra M, Houldsworth J, Dueck A, Rossi M, Mascarenhas J,
Kiladjian JJ, Rampal R, Hoffman R (2020) Transient expansion of TP53 mutated clones in
Polycythemia Vera patients treated with Idasanutlin. Blood Advances 24;4(22):5735-5744. (IF:
7.642). Data acquisition, analysis, and interpretation
32. Nizamaddin SK, Mehrotra M, Nadhim ASH, Luthra R, Chowdhuri SR (2020) Detection of EGFR
T790M mutation by droplet digital polymerase chain reaction in lung carcinoma cytology samples.
Archive Pathology and Laboratory Medicine. doi.org/10.5858/arpa.2019-0411-OA (IF: 5.686).
Conception and design of study, Drafting and revising critically important content.
33. Mascarenhas J, Marcellino BK, Lu M, Kremyanskaya M, Fabris F, Sandy L, Mehrotra M,
Houldsworth J, Najfeld V, Jamal S El, Petersen B, Moshier E, Hoffman R (2020) A phase I study of
panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia
vera/essential thrombocythemia myelofibrosis (post-PV/ET MF) Leukemia Research 88, 106272 (IF:
3.715). Data acquisition, analysis, and interpretation.
13
34. Barrette AM, Ronk H, Joshi T, Mussa Z, Mehrotra M, Bouras A, Nudelman G, Raj JGJ, Bozec D,
Lam W, Houldsworth J, Yong R, Zaslavsky E, Hadjipanayis CG, Birtwistle MR, Tsankova NM
(2022) Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in
preclinical glioblastoma models. Neuro Oncology 4;24(5):694. (IF:15.9). Data acquisition, analysis
and interpretation.
35. Hao Y, Mehrotra M, Lan H, Si Q, Salem F, Lu D, Gitman M, Miles B, Posner M, Houldsworth H,
Westra WH (2021) Liquid phase human papillomavirus genotype analysis of aspirated metastatic
head and neck squamous cell carcinoma: Fine needle aspiration supernatant is a rich source of tumor
DNA that can increase the diagnostic yield. Diagnostic Cytopathology 49(1):25-30 (IF: 1.39).
Conception and design of study, data acquisition, analysis and interpretation.
36. Gelfman LP, Moreno J, Frydman JL, Singer J, Houldsworth J, Cordon-Cardo C, Mehrotra M, Chai
E, Aldridge M, Morrison RS (2022) Characteristics associated with disparities among older adults in
coronavirus disease 2019 Outcomes in an academic health care system. Medical Care. 1;60(5):332-
341 (IF:3.178). Data acquisition, analysis, and interpretation.
37. Doroshow DB, Wei W, Mehrotra M, Sia D, Eder JP, Bindra R, Houldsworth J, LoRusso P, Walther
Z (2023) Platinum sensitivity in IDH1/2 mutated Intrahepatic Cholangiocarcinoma: Not all
"BRCAness" is created equal. Cancer Investigation (7):646-655. (IF: 2.368). Data acquisition,
analysis, and interpretation.
Other Peer Reviewed Publications:
1. Wang X, Haines GK 3rd, Mehrotra M, Houldsworth J, Si Q (2022) Primary hemangioblastoma of
the kidney with molecular analyses by next-generation sequencing: a case report and review of the
Literature. Diagnostic Pathology 17(1):34. (IF:3.196). Data acquisition, analysis, and interpretation.
2. Tomita S, Mehrotra M, Chaoul J, Houldsworth J, Kolev V, Kalir T (2021) A 24 year-old patient
with no prior history of endometriosis diagnosed with bilateral ovarian endometrioid adenocarcinoma
arising in endometriosis. Gynecology Oncology Reports 36:100718. (IF: 0.386). Drafting and
revising critically important content.
3. Chen JM, G Haines K, Lam W, Reddy A, Mehrotra M, Houldsworth J, Si Qi (2021) Urothelial
carcinoma of the graft kidney with molecular analyses: a rare case report. Diagnostic Pathology
16(1):53. (IF: 3.992). Data acquisition, analysis, and interpretation
Books and Book Chapters:
1. Mehrotra M (2016) PCR based detection of DNA copy number variation. Clinical Applications of
PCR. Methods Molecular Biology 1392: 27-32
2. Mehrotra M and Patel K (2016) High resolution melt curve analysis in cancer mutation screen.
Clinical Applications of PCR. Methods Molecular Biology 1392: 63-69
INVITED LECTURES/PRESENTATIONS:
1. Molecular Diagnostics 101 A Primer: Thyroid, Head and Neck Cancer (THANC) Foundation.
https://thancfoundation.org/dr-jane-houldsworth-virtual-journal-club/. (Views: 603)
14
2. Detection of somatic mutations in plasma cell-free nucleic acid by IonTorrent Oncomine cfDNA
assays using Ion S5XL System. Presented at Thermofisher Precision Medical Oncology Workshop
AMP 2017.
Platform presentations in different national and international pathology conferences, including AMP,
USCAP, and CGC, received multiple awards and recognitions.
2013 Assessment of tissue and subcellular distribution of miRNA expressed differentially between
ALK + and ALK- Anaplastic Large Cell Lymphoma at USCAP Annual Meeting, Baltimore,
MD.
2016 Implementation of genotyping cell free nucleic acid in plasma using next generation sequencing
platforms at Cancer Genomic Consortium (CGC), Denver, CO.
2016 Study of Pre-analytic parameters for standardization of cell-free DNA isolation from plasma in a
CLIA-approved Molecular Diagnostics Laboratory at Association of Molecular Pathology
(AMP), Charlotte, NC.
2021 Rapid clinical BRAF V600 mutation testing using Idylla platform at Cancer Genomic
Consortium (CGC). (Virtual talk)
Qualitative detection of EGFR mutations (exons 18 21) in Lung cancer using Idylla platform at
Association of Molecular Pathology, Digital experience (Virtual talk)
2022 Molecular Profiling of Cytolyt-Fixed FNA washes to improve diagnostic yield in Lung Cancer at
Cancer Genomic Consortium (CGC), St Louis, MO.
MEDIA RESOURCE/ EDUCATIONAL MATERIALS
Press Release Coverage by Thermo-Fisher Scientific on development of new NGS S5XL platforms
2015
New Next-Generation Sequencing Platform Simplifies Workflow to Enable Broad Adoption in
Translational and Applied Research .
VOLUNTARY PRESENTATIONS:
Selected Scientific Conference Presentations/Publications:
1. Lu G, Patel K, Miranda R, Medeiros L, Chen T, Mishra B, Abraham R, Muddasani R, Mehrotra M,
Luthra R Genomic analysis by array comparative genomic hybridization of primary myelofibrosis
with isolated del (13q) Poster presentation in Association of Molecular Pathology, October 2012,
Long Beach, CA.
2. Mehrotra M, Luthra R, Singh R, Sargent R, Medeiros L, Patel K Assessment of tissue and
subcellular distribution of mirna expressed differentially between ALK + and ALK- Anaplastic Large
Cell Lymphoma Platform presentation in 102nd USCAP Annual Meeting, March 2013, Baltimore,
MD, USA.
3. Mehrotra M, Luthra R, Barkoha B, Galbincea J, Mehta P, Singh R, Goswami R, Jabbar K, Patel K
Clinical validation of a multi-purpose assay for detection, genotyping and monitoring of CALR
mutations in myeloproliferative neoplasms Poster presentation in Association of Molecular
Pathology, November, 2014, National Harbor, MD. Published in: Journal of Molecular Diagnostic.
15
4. Chen H, Singh R, Abraham R, Mehrotra M, Mishra B, Roy-Chowdhuri S, Routbort M, Aldape K,
Broaddus R, Patel K, Luthra R KRAS amplification in a 73 year-old-man with adenocarcinoma of
lung Poster presentation in Cancer Genomics Consortium and the Cytogenomics Array Group,
August 2014, Swissotel Chicago Published in: Cancer genetics 207(6) 288.
5. Chen H, Luthra R, Kalhor N, Abraham R, Mehrotra M, Mishra B, Patel K, Singh R, Lu X. Unusual
ROS1 translocation pattern in a 61-year-old woman with metastatic adenocarcinoma of lung Poster
presentation in Cancer Genomics Consortium and the Cytogenomics Array Group, August 2015
Denver, CO. Published in: Cancer genetics 208(6) 363.
6. Mehrotra M, Abraham R, Mishra B, Virani S, Patel K, Luthra R and Singh R Validation of
quantitative pcr based assays for detection of copy number aberrations in formalin fixed and paraffin
embedded solid tumor samples Poster presentation in Association of Molecular Pathology,
November 2015, Austin, TX. Published in: Journal of Molecular Diagnostic 17(6) 838.
7. Almohammedsalim A, Luthra R, Ok C, Loghavi S, Mehrotra M, Abraham R, Harmon M, Lu X,
Medeiros L, Patel K, Kanagal R Single nucleotide polymorphism-array-based comparative genomic
hybridization analysis of chronic lymphocytic leukemia/small lymphocytic lymphoma: A study of
168 cases with comparison to traditional genetic testing methods Poster presentation in Association
of Molecular Pathology, November 2015, Austin, TX. Published in: Journal of Molecular
Diagnostic 17(6) 773.
8. Chen H, Lu X, Singh R, Huo L, Bousamra A, Abraham R, Virani S, Mehrotra M, Mishra B, Roy-
Chowdhuri S, Routbort M, Kenneth A, Broaddus R, Yao H, Sahin A, Patel K, Luthra R Quantitative
assessment of ESR, PGR and genome-wide copy number aberrations in advanced breast cancer by
SNP Microarray Poster presentation in Association of Molecular Pathology, Nov2015, Austin, TX.
Published in Journal of Molecular Diagnostic 17(6) 840.
9. Mehrotra M, Hernandez M, Simien C, Barkoh B., Bolivar A, Shi X, Singh R, Gentles K, Abraham
R, Rodriguez S, Cook P, Giffard R, Lentz P, Patel K, Kopetz S, Medeiros L, Wistuba I, Luthra R.
Study of pre-analytic parameters for standardization of cell-free DNA isolation from plasma in a
CLIA-approved Molecular Diagnostics Laboratory Platform presentation in Association of
Molecular Pathology, November 2016, Charlotte, NC. Published in: Journal of Molecular
Diagnostic 18(6) 1019.
10. Mehrotra M, Singh R, Loghavi S, Barkoh B, Simien C, Hernandez M, Manekia J, Behrens
C, Routbort M, Patel K, Kopetz S, Medeiros J, Wistuba I, Luthra R. Ultradeep Sequencing Using
semiconductor-based high-throughput next generation sequencing platforms for cell-free DNA
genotyping in patients with solid tumors Poster presentation in Association of Molecular Pathology,
November 2016, Charlotte, NC. Published in: Journal of Molecular Diagnostic 18(6) 1022.
11. Mehrotra M, Singh R, Barkoh B, Duose D, Patel K, Kopetz S, Medeiros L, Wistuba I, Luthra R.
Comparison of Ultrasensitive droplet digital PCR and MassARRAY platforms for plasma cell-free
DNA genotyping Poster presentation in Association of Molecular Pathology, November 2016,
Charlotte, NC. Published in: Journal of Molecular Diagnostic 18(6) 1046.
12. Mehrotra M, Luthra R, Moreno S, Barkoh B, Burns C, Dailey D, Singh R, Chen W, Routbort M,
Medeiros L, Patel K, Shamanna R Clinical validation of a single-gene next-generation
sequencing-based assay for detection of low-level TP53 gene mutations of the entire coding region
Poster presentation in Association of Molecular Pathology, November 2016, Charlotte, NC.
Published in: Journal of Molecular Diagnostic 18(6) 1047.
13. Mehrotra M, Singh R, Chen W, Huang R, Almohammedsalim A , Barkoh B, Simien C, Hernandez
M, Behrens C, Patel K, Routbort M, Broaddus R, Medeiros L, Wistuba I, Kopetz S, Luthra R
Implementation of genotyping cell free nucleic acid in plasma using next generation sequencing
16
platforms Platform Presentation in Cancer Genomics Consortium Meeting August 2016, Denver,
CO Awarded First place Trainee Award. Published in: Cancer genetics 206(6) 291-292.
14. Evers C, Duose D, Mehrotra M, Hai Tao, Houston M, Hu P, Luthra R Liquid Biopsy: Comparison
of mutation detection methods for measurement of RET M918T circulating cell-free DNA in
Medullary Thyroid cancer patients Platform presentation in Cancer Genomics Consortium (CGC)
Meeting August 2016, Denver, CO Awarded Second Place Technologist Award Published in Cancer
genetics 206(6) 287-288
15. Mehrotra M, Duose D, Singh R, Barkoh B, Maneika J, Yau J, Harmon M, Chen W, Routbort M,
Medeiros L, Wistuba I and Luthra R Scalable next generation sequencing workflow for mutation
screening of solid tumors using Ion S5XL sequencer Poster presentation in USCAP Annual Meeting,
March 2016, Seattle, WA
16. Mehrotra M, Singh R, Chen W, Barkoh B, Behrens C, Patel K, Routbort M, Broaddus R, Medeiros
L, Kopetz S, Wistuba I, Luthra R. Detection of clonal evolution in solid tumors by ultra-deep
sequencing of plasma cell-free nucleic acid using Miseq Platform presentation in USCAP Annual
Meeting, March 2017, San Antonio, TX. Published in: Modern Pathology.
17. Kanagal RS, Mehrotra M, Barkoh B, Mallampati S, Bolivar AM, Chen W, Routbort M, Patel K,
Medeiros LJ Clinical utility of single-gene ultra-deep coverage NGS assay for TP53 mutations for
detection of low-level mutations Poster presentation in Cancer Genomic Consortium, 2018.
Published in: Cancer genetics 226 (2018):56.
18. Marcellino B, Cassinat B, Farnoud N, Lu M, Verger E, McGovern E, Patel MA, Kosiorek HE,
Mehrotra M, Houldsworth J Dueck AC, Rossi M, Kiladjian JJ, Rampal RK, Mascarenhas J,
Hoffman R, Expansion of prior existing TP53 mutated clones in polycythemia vera patients treated
with idasanutlin Platform presentation presented in American Society of Hematology, November
2019, Orlando, FL. Published in: Blood 21 (134), p838.
19. Waluszko A, Stephen T, Choi Y, Sunkara S, Zakowski M, Houldsworth J, Mehrotra M Utility of
salvaged CytoLyt-fixed FNA supernatant for next generation sequencing using Ampliseq Cancer
Hotspot Panel and Oncomine Comprehensive assay: An institutional experience Poster presentation
in Association of Molecular Pathology, November 2019, Baltimore, MD. Published in: Journal of
Molecular Diagnostic 21 (6), p1206.
20. Khan F, Stephen T, Friedman J, Gao D, Miller M., Mehrotra M, Hormigo A, Tsankova N, McBride
R, Houldsworth J The DNA damage repair pathway gene EXO5 is hypermethylated in
Glioblastomas: Correlation with MGMT hypermethylation, genomic alterations and patient outcome
Poster presentation in Association of Molecular Pathology, November 2019, Baltimore, MD.
Published in: Journal of Molecular Diagnostic 21 (6), p1220.
21. Feld J, Houldsworth J, Reddy A, Mai Z, Hussein S, Navada SC, Silverman LR., Mehrotra M. T-
cell monoclonality as assessed by TCR-sequencing: A potential biomarker of response in patients
with MDS with autoimmune cytopenias treated with IVIG . Poster presentation in American Society
of Hematology, December 2020, San Diego, CA. Published in Blood 136; pg 8-9.
22. Mehrotra M, Reddy A, Lam Wi, Waluszko A, Kouame E, Gao D, Houldsworth J Qualitative
detection of EGFR mutations (exons 18 21) in Lung cancer using Idylla platform. Poster
presentation in Association of Molecular Pathology, November 2021, Philadelphia, PA.
23. Mehrotra M, Reddy A, Lam Wi, Waluszko A, Kouame E, Gao D, Houldsworth J Qualitative
Detection of EGFR mutations (exons 18 21) in Lung cancer using Idylla platform. Platform
presentation in Association of Molecular Pathology 2021: Digital Experience (Virtual)
17
24. Mehrotra M, Reddy A, Lam Wi, Waluszko A, Kouame E, Gao D, Sidorenko T, Mai Z, Croken M,
Houldsworth J Rapid clinical BRAF V600 mutation testing using Idylla platform. Platform
presentation in Cancer Genomic Consortium, 2021 (Virtual). Published in: Cancer Genetics
260(2022):3
25. Feld J, Houldsworth J, Reddy A, Mai Z, Hussein S, Navada SC, Silverman LR ., Mehrotra M T cell
receptor sequencing and T-cell monoclonality: A novel biomarker of response to IVIG in MDS
patients with autoimmune cytopenias . Poster presentation in American Society of Hematology,
December 2021, Atlanta, Georgia, Published in: Leukemia Research (2021) 108; 106681.33.
26. Albayrak NE, Liu BL, Mehrotra M, Houldsworth J, Veremis B, Ward SC. Molecular and
immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the
gastroenteropancreatic system. Poster presentation, Pathology Trainee Research Day, Icahn School of
Medicine at Mount Sinai, New York, NY. May 30, 2022
27. Mehrotra M, Lam W, Waluszko A, Kouame E, Zakowski M, Houldsworth J Molecular profiling of
cytolyt-fixed FNA washes to improve diagnostic yield in lung cancer Platform Presentation in
Cancer Genomic Consortium, 2022. Published in: Cancer Genetics (2022) 268 Pg 16-17.
28. Liu B, Molecular Pathology Laboratory, Enriquez M, Ketab HA, Hantash F, Croken M, Mehrotra
M, Houldsworth J Comparison of FISH to whole exome/whole transcriptome detection of relevant
structural alterations in multiple myeloma and monoclonal gammopathies: A single institution
experience. Poster presentation in Cancer Genomic Consortium, 2022.
29. Liu X, Mai Z, Siorenko T, Mehrotra M, Hussein S, Houldsworth J NGS-based detection of clonal
TRG and TRB rearrangements in Myelodysplastic Syndromes patients and correlative
immunophenotype: A Single Institution Experience Poster presentation in USCAP 111Th Annual
Meeting, March 2022, Los Angeles CA. Published in: Lab Investigation (2022) 02 (1), 689
30. Wong J, Lam W, Kouame E, Li L, Haines GK, Mehrotra M, Houldsworth J, Si Q Using next-
generation sequencing to characterize unclassified oncocytic renal cell tumors Poster presentation in
USCAP 111Th Annual Meeting, March 2022, Los Angeles CA. Published in: Lab Investigation
(2022) 02 (1), 981
31. Houldsworth J, Reddy A, Mai Z, Gao D, Sidorenko T, Mehrotra M Clinical laboratory validation
of TCR-seq for detection of clonality. Platform presentation in Cancer Genomic Consortium, 2021
(Virtual). Published in: Cancer Genetics 260(2022): 2.
32. Albayrak NE, Liu BL, Mehrotra M, Houldsworth J, Polydorides AD, Ward SC. Clinicopathologic
and molecular analysis of colorectal carcinomas with varying degrees of neuroendocrine
differentiation. Platform presentation, Pathology Trainee Research Day, Icahn School of Medicine at
Mount Sinai, New York, NY. May 30, 2023. Awarded outstanding scientific presentation in the
Translational/basic Science Category.
33. Mehrotra M, Lam W, Kouame E, Guan M, Baskovich B, Croken M, Houldsworth J. Challenges in
the clinical implementation of the large next-generation sequencing oncomine comprehensive plus
assay, Poster presentation in Cancer Genomic Consortium, 2023, St. Louis, MO. Published in:
Cancer Genetics PHONE NUMBER AVAILABLE: 26
34. Baskovich B, Bogdanova E, Sidorenko T, Mai Z, Parajuli A, Croken M, Mehrotra M, Houldsworth
J. Assessment of TRG and TRB clonality by NGS of dermatologic specimens is impacted by biopsy
type, DNA and amplicon sizes. Platform presentation in Cancer Genomic Consortium, 2023. St.
Louis, MO Published in: Cancer Genetics PHONE NUMBER AVAILABLE: 12.
|
